Tandem snags $36M for touch-screen insulin pump

Tandem Diabetes Care pulled in $36.4 million to market its t:slim insulin pump--courtesy of Tandem Diabetes Care

Tandem Diabetes Care just launched its t:slim touch-screen insulin pump in the U.S., and now the company has $36.4 million to market it, thanks to an in-progress funding round.

Tandem is looking to raise $50 million total, ramping up sales for the device it says is 25% slimmer than other 300-unit insulin pumps. The credit card-sized device got 510(k) clearance last winter, and Tandem began shipping the first t:slim units at the end of August. The device interfaces with the company's t:connect therapy-management software, allowing patients and physician to keep tabs on readings and health data.

The company told MedCity News it estimates the U.S. insulin pump market to be about $1.5 billion, and the global marketplace for diabetes devices is projected to grow to more than $25 billion by 2018, buoyed by regulatory reforms in emerging markets.

And Tandem has further ambitions for its technology. In February, the company inked a deal with DexCom ($DXCM) to share capabilities, looking to pair t:slim with that DexCom's continuous glucose management device, creating an all-in-one diabetes tech.

- here's Tandem's SEC filing
- get more from MedCity News

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.